CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- FinancialsLow earnings quality
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
765.60MUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
1.99xvs all stocks
52-Week Change
-8.28%vs all stocks
Market Capitalization
765.60MUSDvs all stocks (USD)
Enterprise Value
308.19MUSDvs all stocks (USD)
Forward P/E
-3.32xvs Biotechnology peers
Price to Book (MRQ)
1.78xvs Biotechnology peers
Enterprise to EBITDA
-1.40xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-31.82%vs Biotechnology peers
Return on Equity (TTM)
-52.74%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Sep 28, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
-220.68MUSDvs all stocks (USD)
Net Income (TTM)
-204.57MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-164.74MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-89.06MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-178.70MUSDvs all stocks (USD)
Pre-tax Income
-162.45MUSDFY2025 · Dec 31, 2025Net Income
-162.45MUSDFY2025 · Dec 31, 2025EBIT
-178.70MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-178.21MUSDFY2025 · Dec 31, 2025Research & Development
157.70MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
21.00MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
16.22MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-162.45MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-141.30MUSDFY2025 · Dec 31, 2025Free Cash Flow
-141.30MUSDDerived from operating cash flow minus capital expenditure. This filing charges 490K of depreciation against 0 of capital expenditure, and its own free-cash-flow line reads -146.72M.FY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
48.30MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-162.45MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
490.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
17.59MUSDFY2025 · Dec 31, 2025Other Non-cash Items
-5.12MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
4.60MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
3.60MUSDFY2025 · Dec 31, 2025Capital Expenditures
0.00USDFY2025 · Dec 31, 2025Purchase of Investments
-500.72MUSDFY2025 · Dec 31, 2025Sale of Investments
344.96MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-155.76MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
3.00MUSDFY2025 · Dec 31, 2025Other Financing Charges
-6.51MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
201.88MUSDFY2025 · Dec 31, 2025Shares Outstanding
87.45MSharesUpdated Sep 28, 2026Float Shares
59.24MSharesUpdated Sep 28, 2026Shares Short
16.07MSharesUpdated Sep 28, 2026Short Ratio
17.17daysvs all stocks
Short % of Shares Outstanding
22.31%vs all stocks
% Held by Insiders
1.76%vs all stocks
% Held by Institutions
119.52%vs all stocks
Total Cash (MRQ)
461.07MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
5.27USDUpdated Sep 28, 2026Total Debt (MRQ)
3.66MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0085xvs Biotechnology peers
Current Ratio (MRQ)
8.86xvs Biotechnology peers
Book Value per Share (MRQ)
4.92USDUpdated Sep 28, 2026Total Assets
533.43MUSDvs all stocks (USD)
Total Current Assets
515.45MUSDFY2025 · Dec 31, 2025Total Liabilities
54.87MUSDFY2025 · Dec 31, 2025Total Non-current Assets
17.98MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
3.07MUSDFY2025 · Dec 31, 2025Total Current Liabilities
51.80MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
48.30MUSDFY2025 · Dec 31, 2025Other Short-term Investments
457.14MUSDFY2025 · Dec 31, 2025Accounts Payable
9.25MUSDFY2025 · Dec 31, 2025Short-term Debt
1.12MUSDFY2025 · Dec 31, 2025Long-term Debt
3.07MUSDFY2025 · Dec 31, 2025Common Stock (Book)
8.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-597.56MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
478.56MUSDvs all stocks (USD)
52-Week Low
6.65USDUpdated Sep 28, 202652-Week High
36.26USDUpdated Sep 28, 202652-Week Change
-8.28%vs all stocks
Beta
1.99xvs all stocks
50-Day MA
10.81USDUpdated Sep 28, 2026200-Day MA
16.74USDUpdated Sep 28, 2026Avg 10-Day Volume
1.60MSharesUpdated Sep 28, 2026Avg 30-Day Volume
1.11MSharesUpdated Sep 28, 2026Diluted EPS (TTM)
-2.12USDUpdated Sep 28, 2026Other Income / Expense
23.00KUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.64
Altman Z-Score 6.74: safe zoneNotable
Altman Z-Score: 6.74
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 33,357,653.812
Companies that share the same coordination system — how they create, deliver, or capture value.
Getein Biotech Inc.
Tier 1ProductionApproval-Gated PipelineRule
Boji Medical & Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Kexing Biopharm Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Obio Technology (Shanghai) Corp., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Design Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Aclaris Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Heilongjiang ZBD Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Tong Ren Tang Technologies Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Achieve Life Sciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Tibet Duorui Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule